Loading...
•
Sep 30, 2022
Regeneron Q3 2022 Earnings Report
Reported a decrease in revenue due to the absence of REGEN-COV sales, but experienced growth in key products like EYLEA and Dupixent.
Key Takeaways
Regeneron's Q3 2022 revenues decreased by 15% to $2.94 billion, but excluding REGEN-COV, revenues increased by 11%. EYLEA U.S. net sales increased by 11% to a record $1.63 billion, while Dupixent global net sales increased by 40% to $2.33 billion. The company reported GAAP diluted EPS of $11.66 and non-GAAP diluted EPS of $11.14.
Total revenues decreased 15% to $2.94 billion; excluding REGEN-COV, revenues increased 11%.
EYLEA U.S. net sales increased 11% to a record $1.63 billion.
Dupixent global net sales increased 40% to $2.33 billion.
GAAP diluted EPS was $11.66, and non-GAAP diluted EPS was $11.14.
Revenue by Segment
Forward Guidance
Regeneron provided full year 2022 financial guidance for R&D, SG&A, Gross margin on net product sales, COCM, Other operating (income) expense, net, Capital expenditures, and Effective tax rate.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...